The Crux Between Large Language Models and Clinical Trials

Daniel: We are really seeing a bottleneck. There's almost, especially as we come out of pandemic, that we've seen a lot of change really fast. And I think it's too soon to be talking about complete autonomization of health care and life sciences workflows. Daniel: For certain activities in a clinical trial, it's not going to be happening for, I think, four years plus. But for other things, it's going to be really fast. It's a race who can get there first. On behalf of Daniel and everyone here at eMERGE, thanks so much for joining us today.